跳至主要内容
临床试验/NCT03489226
NCT03489226已完成不适用

A Pilot Study of the Effect of a Dietary Herbal Supplement Containing Capsaicin or Placebo on Satiety, Metabolic Rate and Food Intake in Healthy Adults.

Pennington Biomedical Research Center2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2016年5月2日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
24
试验地点
2
主要终点
Resting Metabolic Rate

研究概览

简要总结

Comparison of Capsimax™ 2mg and 4mg of capsicum extract vs. placebo on metabolic rate and satiety.

详细描述

Capsimax™ is a capsicum extract in a bead technology to avoid oral and gastric burning. Capsimax™ 2mg, Capsimax™ 4 mg and placebo was initially given as a single dose on an empty stomach with measures of metabolic rate, and satiety before and after and food intake at 1 hour after Capsimax™.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

盲法说明

Supplement and placebo capsules with identical appearance

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • BMI between 25 and 40 kg/m2 inclusive
  • If of child-bearing potential, use of effective contraception

排除标准

  • Subjects excluded will:
  • Have received an investigational product in another trial within 30 days of enrollment.
  • Have lost 10 or more pounds in the 3 months prior to randomization and maintained the weight loss.
  • Use tobacco products
  • Use a nicotine patch or gum.
  • Take regular medication other than oral contraceptives or estrogen replacement therapy.
  • Take products containing ephedra or medications known to increase metabolic rate like stimulants taken for attention deficit disorder.
  • Not eat at regular mealtimes.
  • Have a history of alcohol or drug abuse in the past year.
  • Nurse a baby or be a member of a vulnerable population including adults unable to consent, pregnant women, prisoners or minors.
  • Have a clinically significant history of diabetes, high blood pressure (>140/90), thyroid disease, heart disease, kidney disease or liver disease.
  • Have a known allergy to capsaicin caffeine, piperine or niacin.
  • Have clinically significant laboratory findings in the opinion of the investigator.
  • Score greater than 13 on the restraint scale of the 3-factor eating questionnaire.

研究组 & 干预措施

Capsimax 2 mg

Active Comparator

single dose with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.

干预措施: Capsimax (Dietary Supplement)

Placebo

Placebo Comparator

single dose with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.

干预措施: Placebo (Dietary Supplement)

Capsimax 4 mg plus 250 kcal meal

Active Comparator

single dose with 250 kcal meal with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.

干预措施: Capsimax (Dietary Supplement)

Capsimax 4 mg plus 250 kcal meal

Active Comparator

single dose with 250 kcal meal with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.

干预措施: Meal (Other)

Placebo plus 250 kcal meal

Placebo Comparator

single dose with 250 kcal meal with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.

干预措施: Placebo (Dietary Supplement)

Placebo plus 250 kcal meal

Placebo Comparator

single dose with 250 kcal meal with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.

干预措施: Meal (Other)

结局指标

主要结局

Resting Metabolic Rate

时间窗: up to 5 hours

Metabolic cart measurement difference before and after intervention

次要结局

  • Satiety by Visual Analog Scale (hunger, fullness, prospective food intake and satisfaction)(Baseline to 4 hours)
  • Food Intake(1 hour after intervention)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Frank Greenway

Medical Director and Professor

Pennington Biomedical Research Center

研究点 (2)

Loading locations...

相似试验